Scientists in Japan may be at the start of a truly monumental accomplishment: a vaccine that can slow or delay the progression of Alzheimer’s disease. In preliminary research released this week ...

According to Japan's National Institute of Population and Social Security Research, people aged over 65 are expected to account for 32.3% of the country's population by 2035.

A new Alzheimer's drug is offering hope for the millions of dementia sufferers among Japan's rapidly aging population. While it is yet to be approved in Japan, regulators in the United States have ...

Meanwhile, 2022 also saw Roche receive a breakthrough designation from the FDA for its in vitro Alzheimer’s test—an amyloid plasma panel that also measures blood levels of phosphorylated tau ...

The research was published in the medical journal Alzheimer's Research & Therapy on Nov. 21. In a time of both misinformation and too much information, quality journalism is more crucial than ever.

Japanese researchers have confirmed a way to predict the onset of Alzheimer’s disease with a high degree of probability, by checking blood for the presence of a certain type of abnormal protein ...

Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive ...

Commentary Published: 01 July 2006 Alzheimer disease research in Japan: public funding Takeshi Iwatsubo, Yasuo Ihara & Ichiro Kanazawa Nature Medicine 12, 778–779 (2006) Cite this article ...

Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

It will make a huge difference.” “If you go back 10 or 15 years, we couldn’t even say for sure that you had Alzheimer’s because it couldn’t be confirmed until autopsy,” says Shallcross.

The optimism about Alzheimer’s was palpable in Kyoto, along with the cherry blossoms and beginning of Golden Week. The WHO’s target date of 2025 for finding a cure now seems to be in reach.